Ziftomenib in Relapsed or Refractory <i>NPM1</i> -Mutated AML
Jordi Esteve Reyner, Arnaud Pigneux(Centre Hospitalier Universitaire de Bordeaux), Pau Montesinos(Instituto de Salud Carlos III), James McCloskey(Hackensack University Medical Center), Lionel Adès(Délégation Paris 7), Marcie Riches(Medical College of Wisconsin), Mohamad Khawandanah(University of Oklahoma Health Sciences Center), Adolfo de la Fuente, Gail J. Roboz(Cornell University), Mithun Vinod Shah(Mayo Clinic in Arizona), Pierre Péterlin(Hotel Dieu Hospital), Jessica K. Altman(Northwestern University), Amitava Mitra(Kura Oncology (United States)), James M. Foran(Memorial Sloan Kettering Cancer Center), Daniel Corum(Fujikura (United States)), Robert L. Redner(UPMC Hillman Cancer Center), Harris S. Soifer(Kura Oncology (United States)), Cristina Papayannidis(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Maria R. Baer(University of Maryland, Baltimore), Harry P. Erba(Michigan Center for Translational Pathology), Dries Deeren(Inagro (Belgium)), Frédéric Barabé(Universitat Autònoma de Barcelona), Marilyn Tabachri(Kura Oncology (United States)), Kristen Pettit(University of Michigan), Eduardo Rodríguez‐Arbolí(Instituto de Biomedicina de Sevilla), Amir T. Fathi(Harvard University), Suresh Kumar Balasubramanian(Cleveland Clinic), Yazan F. Madanat(The University of Texas Southwestern Medical Center), Zijing Zhang, Florian H. Heidel(Medizinische Hochschule Hannover), Mahmoud Elsawy(Dalhousie University), Mollie Leoni(Kura Oncology (United States))
Cited by 33
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k